Therefore, pharmacological inhibition of TGF-β [193] or engineering the TGF-β receptor on NK cells can potentially overcome TGF-β-mediated inhibition and enhance NK anti-cancer activity [194–196]. The gene discussed is TGFB1; the disease is cancer.